REG - Beximco Pharma. - Board Changes

Beximco PharmaceuticalsAnnouncement

29/01/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250129:nRSc0172Va&default-theme=true

RNS Number : 0172V  Beximco Pharmaceuticals Ltd  29 January 2025

 

29 January 2025

BEXIMCO PHARMACEUTICALS LIMITED

Board Changes

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or the "Company"; AIM
Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of
generic pharmaceutical products and active pharmaceutical ingredients,
announces that Ms. Quamrun Naher Ahmed, a Non-Executive Director since 30
November 2020, has been replaced by Mr. Mohammed Ebtadul Islam, both with
immediate effect. Mr. Islam, like Ms. Ahmed previously, has been nominated to
this position by IFIC Bank PLC, a shareholder in the Company, and he will
serve as a Non-Executive Director.

Mr. Islam has extensive expertise in finance and management at a senior level,
having worked at Bangladesh Bank, the central bank of Bangladesh, for 33
years, retiring as an Executive Director in 2014. He currently serves as an
independent director of IFIC Bank PLC, a leading full-service private bank
based in Dhaka. He is also a Supernumerary Professor at the Bangladesh
Institute of Bank Management (BIBM), the national educational institute on
banking and finance in Bangladesh.

Mr. A S F Rahman - Chairman of Beximco Pharmaceuticals, commented:

"On behalf of the Board, I would like to thank Ms. Quamrun Naher Ahmed for her
contribution to the Board over the past four years, and wish her all the very
best for the future.

I am delighted to announce that Mr. Ebtadul Islam is joining Beximco Pharma's
Board. He has deep experience from a long career at Bangladesh Bank and we are
excited for him to bring this to bear at Beximco Pharma. We are looking
forward to working with him as we continue to maintain our focus on growing
the business and delivering shareholder value."

Additional disclosure information required by Schedule 2(g) of the AIM Rules
for Companies

Mr. Mohammed Ebtadul Islam

In addition to his appointment to the board, Mr. Mohammed  Ebtadul Islam,
aged 69, holds (or has held) the following directorships/partnerships in the
past five years:

 Current directorships/partnerships  Previous directorships/partnerships
 IFIC Bank PLC                       None
 IFIC Money Transfer (UK) Limited
 IFIC Investment Limited

Neither Mr. Islam, nor any person closely associated with him, has any direct
or indirect personal interest in the shares of Beximco Pharmaceuticals
Limited. As noted above, Mr. Islam has been nominated to the position of
Non-Executive Director by IFIC Bank PLC.

 

There is no further information to be disclosed pursuant to paragraph (g) of
Schedule 2 of the AIM Rules.

 

For further information please visit www.beximcopharma.com or enquire to:

 

Beximco Pharma

Mohammad Ali Nawaz, Chief Financial Officer

Tel: +880 2 58611001, Ext.20030

 

Mohammad Asad Ullah, FCS

Executive Director & Company Secretary

Tel: +880 2 41060531, Ext. 10140

 

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott

Tel: +44 (0) 20 3368 3551 / 3555

 

SP Angel Corporate Finance LLP (Broker)

Matthew Johnson

Tel: +44 (0) 20 3470 0470

 

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0) 20 3727 1000

 

Notes to Editors

 

About Beximco Pharmaceuticals Limited

 

Beximco Pharma is a leading manufacturer and exporter of medicines based in
Bangladesh. Since its inception in 1976, the Company remains committed to
health and wellbeing of people across all the continents by providing access
to contemporary medicines. Company's broad portfolio of generics encompasses
diverse delivery systems such as tablets, capsules, liquids, semi-solids,
intravenous fluids, metered dose inhalers, dry powder inhalers, sterile
ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser
solutions, oral soluble films etc. The Company also undertakes contract
manufacturing for multinational and leading global generic pharmaceutical
companies.

 

Beximco Pharma′s state-of-the-art manufacturing facilities are certified by
global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin
America, among others and it has a geographic footprint in more than 50
countries. More than 6000 employees are driving the company towards achieving
its aspiration to be among the most admired companies in the region.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAPPUQGGUPAGMR